Home
About Us
Structure
Current Events
Past Events
Video Gallery
Policy & Reports
Awards
Membership
Media Coverage
Internship/Volunteers
Legal
Contact Us
 
 

USAIC has created an ecosystem committed to driving a global dialogue on BioPharma & Healthcare innovation, attracting a diverse mix of senior industry professionals and catalyzing partnerships, new ideas, networks and regulatory reform. This unique platform creates mutually beneficial opportunities and relationships for the global Life Sciences & Healthcare industry.

Registration is closed. Thanks for your overwhelming response. See you at 2021 summit- June 22. Marriott Cambridge, Massachusetts, USA
14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST - Virtual Edition
Registration is closed
The Summit has reached full capacity. Registration is closed. There is no onsite registration.
Thanks for your overwhelming response. See you at 2020 summit!

Poll Questions for September 4

Polling Time (EST) Polling Topic
8-50 AM COVID-19 Panel

Question 1: What do you foresee as the most likely outcome of the race to develop a vaccine?

  • Heightened international tensions due to inequities in distribution
  • Use of the vaccine as an instrument of geopolitics
  • Collaboration between governments to use vaccine to end the pandemic
  • All of the above

Question 2: What minimum criteria would you like to see for approval of COVID19 vaccines, assuming adequate efficacy?

  • Immune response in people over 60 years
  • Durability of response
  • Antibody plus T-cell response
  • Emergency Use Authorization with caveats followed by final approval
9-10 AM India Regulatory Update

How will MNCs respond to the recent regulatory changes for BioPharmas in India? They are _____ to run clinical trials there:

  • More likely
  • Less likely
  • Equally likely
9-55 AM Fireside Chat: Ken Frazier

The BioPharma industry this year has publicly committed itself to greater diversity. What specific measures do you expect to see?
  • Increasing diversity in clinical trials
  • Increasing diversity at the C-suite and board level
  • Increasing diversity throughout the company
  • All of the above
  • None of the above
10-40 AM India Innovation Landscape

What is the most important step India could take to become a global leader in life sciences innovation?”

  • Implement government policies to incentivize innovative drug development
  • Increase availability of financing for BioPharmas
  • Improve clinical trial infrastructure
  • Increase IP protection
11-25 AM Oncology Panel

Question 1:

Changes in policy and reimbursement over the next five years will impact innovation in cancer therapeutics

  • Not at all
  • Slightly
  • Moderately
  • Significantly

Question 2: What therapeutic innovation do you think will have the biggest impact on cancer in the next five years?

  • Cell-based immunotherapies
  • Antibody-based immunotherapies
  • Bispecific / multi-specific antibodies
  • Antibody drug conjugates
12-10 PM Industry & Investment Outlook Panel

More and more funding has been going into preclinical companies -- do you expect this trend to continue?

  • Yes
  • No

R&D Strategies and Trends Panel

COVID-19 has led to an unprecedented level of collaboration among stakeholders in the biopharma industry. Where do you expect to see the biggest increase in collaborations post-pandemic?

  • Discovery/preclinical research
  • Clinical development
  • Manufacturing
  • Commercialization
1 PM Rare Diseases Panel

What is the biggest barrier to access to Orphan drugs in low-income countries?

  • Price, Access and Availability
  • Disease recognition and diagnosis
  • Lack of patient education regarding new therapies
1-50 PM Fireside Chat: Roy Vagelos

Question 1:

Will pharma’s reputation continue its positive trend or return to negative base line beyond the pandemic

  • Yes
  • No

Question 2:

COVID-19 has put the spotlight on BioPharma as an essential player in the return to normalcy. What primary action do you think the industry needs to take to maintain a positive reputation beyond the pandemic?

  • Continue developing innovative drug pricing models
  • Increase drug pricing transparency
  • Increase data sharing and transparency
  • Improving availability and access in low income countries
2-35 PM Digital & Data Sciences Panel

Where has COVID-19 had the biggest impact on your adoption and use of digital health technologies?

  • Remote clinical trials and patient monitoring
  • Real-world data collection and analysis
  • Virtual drug launches

 

Pharmasia News   Biospectrum India Online
 



























© 2007 - USA India Chamber of Commerce Home | About us | | Policy | Events | Photo Gallery | Awards | Membership | Media Coverage | | Legal | Contact us